Genomic Predictors of Papillary Microcarcinoma Disease Progression
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The study is being done to answer the following question: What are the specific clinical and molecular features that will help us predict which small thyroid cancers are likely to grow and be problematic? Therefore, the purpose of this study is to identify specific clinical and molecular characteristics that are predictive of tumor progression in small thyroid cancers.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Biopsy proven papillary thyroid cancer (or suspicious for papillary thyroid cancer) confirmed by MSKCC cytopathologist.
• Being followed with active surveillance at MSKCC
• Biopsied index nodule less than or equal to 2 cm in maximum dimension
• Thyroid and neck US performed and interpreted by a MSKCC radiologist within 6 months prior to study entry.
Locations
United States
New York
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Contact Information
Primary
Robert Tuttle, MD
646-888-2716
Backup
Michael Berger, PhD
646-888-3386
Time Frame
Start Date: 2014-12-31
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 500
Treatments
Papillary Microcarcinoma
This clinical trial protocol describes implementation of a prospective observation protocol to standardize data collection and obtain permission to collect samples of PMC tumors in a cohort of PMC patients being followed with active surveillance. This will allow PMC tumors to be accurately classified as either stable or progressive over time and used for comprehensive molecular profiling if surgical removal is required during follow-up
Related Therapeutic Areas
Sponsors
Leads: Memorial Sloan Kettering Cancer Center
Collaborators: University of Pittsburgh, Ohio State University